NEW YORK (Reuters) -Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company’s bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc., which has sued both Metsera and Novo over the terms of their rival deal.
“As of today, our bid is higher, and our message to Pfizer is that if they would like to buy the company, then put your hand in the pocket and bid higher,” Doustdar said.
(Reporting by Bhargav Acharya)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
Comments